These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 24291780

  • 1. Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir.
    Kulkarni R, Feng JY, Miller MD, White KL.
    Antiviral Res; 2014 Jan; 101():131-5. PubMed ID: 24291780
    [Abstract] [Full Text] [Related]

  • 2. The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.
    Feng JY, Ly JK, Myrick F, Goodman D, White KL, Svarovskaia ES, Borroto-Esoda K, Miller MD.
    Retrovirology; 2009 May 13; 6():44. PubMed ID: 19439089
    [Abstract] [Full Text] [Related]

  • 3. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
    Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, Bloch M, Garner W, Guyer B, Williams S, Chuck S, Vanveggel S, Deckx H, Stevens M.
    HIV Clin Trials; 2013 May 13; 14(3):81-91. PubMed ID: 23835510
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
    Lambert-Niclot S, Charpentier C, Storto A, Fofana D, Soulie C, Fourati S, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG.
    J Antimicrob Chemother; 2014 Apr 13; 69(4):1086-9. PubMed ID: 24302653
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
    Behrens G, Rijnders B, Nelson M, Orkin C, Cohen C, Mills A, Elion RA, Vanveggel S, Stevens M, Rimsky L, Thorpe D, Bosse M, White K, Zhong L, DeMorin J, Chuck SK.
    AIDS Patient Care STDS; 2014 Apr 13; 28(4):168-75. PubMed ID: 24660840
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
    Porter DP, Kulkarni R, Fralich T, Miller MD, White KL.
    J Acquir Immune Defic Syndr; 2014 Mar 01; 65(3):318-26. PubMed ID: 24525469
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro.
    Andreatta K, Miller MD, White KL.
    J Acquir Immune Defic Syndr; 2013 Apr 01; 62(4):367-74. PubMed ID: 23187937
    [Abstract] [Full Text] [Related]

  • 15. Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine.
    Ray AS, Myrick F, Vela JE, Olson LY, Eisenberg EJ, Borroto-Esodo K, Miller MD, Fridland A.
    Antivir Ther; 2005 Apr 01; 10(3):451-7. PubMed ID: 15918336
    [Abstract] [Full Text] [Related]

  • 16. The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro.
    Kulkarni R, Hluhanich R, McColl DM, Miller MD, White KL.
    Antimicrob Agents Chemother; 2014 Oct 01; 58(10):6145-50. PubMed ID: 25092710
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
    Xu HT, Colby-Germinario SP, Huang W, Oliveira M, Han Y, Quan Y, Petropoulos CJ, Wainberg MA.
    Antimicrob Agents Chemother; 2013 Nov 01; 57(11):5649-57. PubMed ID: 24002090
    [Abstract] [Full Text] [Related]

  • 19. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
    Wilkins EL, Cohen CJ, Trottier B, Esser S, Smith DE, Haas B, Brinson C, Garner W, Chuck S, Thorpe D, De-Oertel S.
    AIDS Care; 2016 Nov 01; 28(3):401-8. PubMed ID: 26489045
    [Abstract] [Full Text] [Related]

  • 20. Mathematical Modelling of the Molecular Mechanisms of Interaction of Tenofovir with Emtricitabine against HIV.
    Iannuzzi S, von Kleist M.
    Viruses; 2021 Jul 13; 13(7):. PubMed ID: 34372560
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.